文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌腔内治疗的系统综述

A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2025-11-14

该系统综述评估了上尿路尿路上皮癌(UTUC)腔内治疗(免疫或化疗消融)的疗效、复发率和不良事件。纳入11篇文章(9项研究,368例患者),其中4项针对原位癌(CIS),5项针对乳头状UTUC。CIS中BCG免疫治疗完全缓解率72.7%-100%,12个月持续缓解率63.6%-80%;乳头状UTUC中丝裂霉素凝胶化疗消融完全缓解率36.4%-57.7%。结论认为腔内治疗对特定患者有效且安全,可作为保留肾脏的替代方案。

要点

  • BCG治疗上尿路CIS的完全缓解率可达72.7%-100%,12个月持续缓解率63.6%-80%。
  • 丝裂霉素凝胶治疗乳头状UTUC的完全缓解率为36.4%-57.7%,12个月无复发生存率13.6%-53.1%。
  • 腔内治疗不良事件包括输尿管狭窄(4.5%-10%)、血尿(3.1%-32.8%)和腰痛(18.8%-34.4%)。

核心结论

  • 腔内治疗(CIS用BCG,乳头状病变用丝裂霉素C)显示出可观疗效和可接受的安全性。
  • 这些疗法为不适合手术或肾功能衰竭高风险患者提供了保留肾脏的替代选择,证据支持在精心筛选的患者中使用。

研究设计与样本

  • 系统综述,方案注册于PROSPERO并遵循PRISMA指南。
  • 检索MEDLINE、Embase和Cochrane数据库(2024年10月),纳入随机和非随机研究及单臂研究。
  • 共纳入11篇文章,报告9项独特研究,总计368例患者;4项研究针对上尿路CIS,5项针对乳头状UTUC。

主要发现

  • CIS中BCG免疫治疗的完全缓解率为72.7%-100%,12个月持续缓解率为63.6%-80%。
  • 上尿路CIS中吉西他滨-多西他赛灌注的12个月无复发生存率为78%。
  • 乳头状UTUC中丝裂霉素凝胶(UGN-101)化疗消融的完全缓解率为36.4%-57.7%,12个月无复发生存率为13.6%-53.1%。
  • 不良事件包括输尿管狭窄(4.5%-10%)、血尿(3.1%-32.8%)和腰痛(18.8%-34.4%)。

临床怎么用

  • 对于不适合手术或肾功能衰竭高风险的精选UTUC患者,可考虑腔内治疗作为保留肾脏的替代方案。
  • CIS患者可考虑BCG免疫治疗,乳头状UTUC患者可考虑丝裂霉素凝胶化疗消融。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Radical nephroureterectomy is the standard of care for management of upper tract urothelial carcinoma (UTUC), but treatment-associated morbidity is not uncommon. Intracavitary therapy has emerged as a less invasive alternative for selected cases, particularly carcinoma in situ (CIS) and low-grade papillary tumors. We conducted a systematic review to evaluate the outcomes, recurrence rates, and adverse events associated with intracavitary therapy (immunotherapy or chemoablation) for UTUC. METHODS: The review protocol was registered on PROSPERO and adhered to PRISMA guidelines. The MEDLINE, Embase, and Cochrane databases were searched in October 2024 using terms related to UTUC and intraluminal therapy. Both randomized and nonrandomized studies and single-arm studies were included. KEY FINDINGS AND LIMITATIONS: We included 11 articles reporting on nine unique studies (368 patients in total) in the review. Four studies were in upper tract CIS and five were in papillary UTUC. For CIS, Bacillus Calmette-Guérin immunotherapy resulted in a CR rate ranging from 72.7% to 100%, and a 12-mo persistent response rate of 63.6-80%. For gemcitabine-docetaxel instillation in upper-tract CIS, the recurrence-free survival rate at 12 mo was 78%. For papillary UTUC, chemoablation with mitomycin gel (UGN-101) achieved CR rates of 36.4-57.7%, with 12-mo recurrence-free survival rates ranging from 13.6% to 53.1%. Adverse events included ureteric stricture (4.5-10%), hematuria (3.1-32.8%), and loin pain (18.8-34.4%). CONCLUSIONS AND CLINICAL IMPLICATIONS: Intracavitary therapy for UTUC in the form of BCG for CIS and mitomycin C for papillary disease shows considerable efficacy, with acceptable safety profiles. These therapies represent a renal-preserving alternative for patients unfit for surgery or at high risk of renal failure, and the evidence supports their use in carefully selected patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wong CH, Leung DK, Ko IC, et al. A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2025. PMID: 41241654. doi:10.1016/j.euo.2025.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。